The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics

Adam G. Dunn, Liat Orenstein, Enrico Coiera, Kenneth D. Mandl, Florence T. Bourgeois

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objective: To determine whether certain trial characteristics are associated with faster or more frequent inclusion in systematic reviews for drug interventions in type 2 diabetes. Study Design and Setting: We examined trials included in systematic reviews published between January 1, 2007 and January 1, 2017. Primary outcomes were time between trial publication and first inclusion in a systematic review and frequency of inclusion in systematic reviews over the study period. Multivariable Cox proportional hazards and regression models quantified associations with funding source, number of participants, trial conclusion, and journal impact factor. Results: Among 668 trials, the median time to inclusion was 76.1 weeks. Time to inclusion was shorter for trials with industry funding (hazard ratio [HR] 1.39; 95% confidence interval [CI] 1.13–1.71), more participants (HR 1.26; 95% CI 1.17–1.36), and published in higher impact factor journals (HR 1.28; 95% CI 1.14–1.45). The median frequency of inclusion was three. Frequency of inclusion was greater for trials with industry funding (relative risk [RR] 2.36; 95% CI 2.11–2.64), more participants (RR 1.51; 95% CI 1.47–1.55), positive conclusions (RR 1.89; 95% CI 1.68–2.13), and published in higher impact factor journals (RR 1.13; 95% CI 1.08–1.18). Conclusion: Certain trial characteristics are associated with faster or more frequent trial inclusion in systematic reviews of type 2 diabetes.

LanguageEnglish
Pages62-69
Number of pages8
JournalJournal of Clinical Epidemiology
Volume109
DOIs
Publication statusPublished - 1 May 2019

Fingerprint

Type 2 Diabetes Mellitus
Confidence Intervals
Journal Impact Factor
Pharmaceutical Preparations
Industry
Proportional Hazards Models
Publications

Keywords

  • Clinical trial as a topic
  • Industry funding
  • Randomized controlled trials
  • Systematic review as a topic
  • Systematic review biases
  • Type 2 diabetes

Cite this

@article{5fd2a7d290a34112a47f2babe0228406,
title = "The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics",
abstract = "Objective: To determine whether certain trial characteristics are associated with faster or more frequent inclusion in systematic reviews for drug interventions in type 2 diabetes. Study Design and Setting: We examined trials included in systematic reviews published between January 1, 2007 and January 1, 2017. Primary outcomes were time between trial publication and first inclusion in a systematic review and frequency of inclusion in systematic reviews over the study period. Multivariable Cox proportional hazards and regression models quantified associations with funding source, number of participants, trial conclusion, and journal impact factor. Results: Among 668 trials, the median time to inclusion was 76.1 weeks. Time to inclusion was shorter for trials with industry funding (hazard ratio [HR] 1.39; 95{\%} confidence interval [CI] 1.13–1.71), more participants (HR 1.26; 95{\%} CI 1.17–1.36), and published in higher impact factor journals (HR 1.28; 95{\%} CI 1.14–1.45). The median frequency of inclusion was three. Frequency of inclusion was greater for trials with industry funding (relative risk [RR] 2.36; 95{\%} CI 2.11–2.64), more participants (RR 1.51; 95{\%} CI 1.47–1.55), positive conclusions (RR 1.89; 95{\%} CI 1.68–2.13), and published in higher impact factor journals (RR 1.13; 95{\%} CI 1.08–1.18). Conclusion: Certain trial characteristics are associated with faster or more frequent trial inclusion in systematic reviews of type 2 diabetes.",
keywords = "Clinical trial as a topic, Industry funding, Randomized controlled trials, Systematic review as a topic, Systematic review biases, Type 2 diabetes",
author = "Dunn, {Adam G.} and Liat Orenstein and Enrico Coiera and Mandl, {Kenneth D.} and Bourgeois, {Florence T.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.jclinepi.2019.01.009",
language = "English",
volume = "109",
pages = "62--69",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier",

}

The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics. / Dunn, Adam G.; Orenstein, Liat; Coiera, Enrico; Mandl, Kenneth D.; Bourgeois, Florence T.

In: Journal of Clinical Epidemiology, Vol. 109, 01.05.2019, p. 62-69.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics

AU - Dunn, Adam G.

AU - Orenstein, Liat

AU - Coiera, Enrico

AU - Mandl, Kenneth D.

AU - Bourgeois, Florence T.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Objective: To determine whether certain trial characteristics are associated with faster or more frequent inclusion in systematic reviews for drug interventions in type 2 diabetes. Study Design and Setting: We examined trials included in systematic reviews published between January 1, 2007 and January 1, 2017. Primary outcomes were time between trial publication and first inclusion in a systematic review and frequency of inclusion in systematic reviews over the study period. Multivariable Cox proportional hazards and regression models quantified associations with funding source, number of participants, trial conclusion, and journal impact factor. Results: Among 668 trials, the median time to inclusion was 76.1 weeks. Time to inclusion was shorter for trials with industry funding (hazard ratio [HR] 1.39; 95% confidence interval [CI] 1.13–1.71), more participants (HR 1.26; 95% CI 1.17–1.36), and published in higher impact factor journals (HR 1.28; 95% CI 1.14–1.45). The median frequency of inclusion was three. Frequency of inclusion was greater for trials with industry funding (relative risk [RR] 2.36; 95% CI 2.11–2.64), more participants (RR 1.51; 95% CI 1.47–1.55), positive conclusions (RR 1.89; 95% CI 1.68–2.13), and published in higher impact factor journals (RR 1.13; 95% CI 1.08–1.18). Conclusion: Certain trial characteristics are associated with faster or more frequent trial inclusion in systematic reviews of type 2 diabetes.

AB - Objective: To determine whether certain trial characteristics are associated with faster or more frequent inclusion in systematic reviews for drug interventions in type 2 diabetes. Study Design and Setting: We examined trials included in systematic reviews published between January 1, 2007 and January 1, 2017. Primary outcomes were time between trial publication and first inclusion in a systematic review and frequency of inclusion in systematic reviews over the study period. Multivariable Cox proportional hazards and regression models quantified associations with funding source, number of participants, trial conclusion, and journal impact factor. Results: Among 668 trials, the median time to inclusion was 76.1 weeks. Time to inclusion was shorter for trials with industry funding (hazard ratio [HR] 1.39; 95% confidence interval [CI] 1.13–1.71), more participants (HR 1.26; 95% CI 1.17–1.36), and published in higher impact factor journals (HR 1.28; 95% CI 1.14–1.45). The median frequency of inclusion was three. Frequency of inclusion was greater for trials with industry funding (relative risk [RR] 2.36; 95% CI 2.11–2.64), more participants (RR 1.51; 95% CI 1.47–1.55), positive conclusions (RR 1.89; 95% CI 1.68–2.13), and published in higher impact factor journals (RR 1.13; 95% CI 1.08–1.18). Conclusion: Certain trial characteristics are associated with faster or more frequent trial inclusion in systematic reviews of type 2 diabetes.

KW - Clinical trial as a topic

KW - Industry funding

KW - Randomized controlled trials

KW - Systematic review as a topic

KW - Systematic review biases

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85061653218&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2019.01.009

DO - 10.1016/j.jclinepi.2019.01.009

M3 - Article

VL - 109

SP - 62

EP - 69

JO - Journal of Clinical Epidemiology

T2 - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

ER -